Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.
The potent new antiviral inhibitor GRL-98065 (1) of HIV-1 protease (PR) has been studied with PR variants containing the single mutations D30N, I50V, V82A, and I84V that provide resistance to the major clinical inhibitors. Compound 1 had inhibition constants of 17-fold, 8-fold, 3-fold, and 3-fold, respectively, for PR(D30N), PR(I50V), PR(V82A), and PR(I84V) relative to wild type PR. The chemically related darunavir had similar relative inhibition, except for PR(D30N), where inhibitor 1 was approximately 3-fold less potent. The high resolution (1.11-1.60 Angstrom) crystal structures of PR mutant complexes with inhibitor 1 showed small changes relative to the wild type enzyme. PR(D30N) and PR(V82A) showed compensating interactions with inhibitor 1 relative to those of PR, while reduced hydrophobic contacts were observed with PR(I50V) and PR(I84V). Importantly, inhibitor 1 complexes showed fewer changes relative to wild type enzyme than reported for darunavir complexes. Therefore, inhibitor 1 is a valuable addition to the antiviral inhibitors with high potency against resistant strains of HIV.
Wang
Yuan-Fang
YF
Department of Biology, Molecular Basis of Disease, Georgia State University, Atlanta, Georgia 30303, USA.
Tie
Yunfeng
Y
Boross
Peter I
PI
Tozser
Jozsef
J
Ghosh
Arun K
AK
Harrison
Robert W
RW
Weber
Irene T
IT
D018360:Crystallography, X-Ray; D000069454:Darunavir; D024882:Drug Resistance, Viral; D016333:HIV Protease / Q000737:chemistry* / Q000235:genetics; D017320:HIV Protease Inhibitors / Q000737:chemistry*; D008958:Models, Molecular; D015394:Molecular Structure; D009154:Mutation; D013449:Sulfonamides / Q000737:chemistry*
C522027:(2,8-dioxabicyclo(3.3.0)oct-6-yl)-N-(4-((3,4-methylenedioxyphenyl)sulfonyl-(2-methylpropyl)amino)-3-hydroxy-1-phenylbutan-2-yl) carbamate; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D016333:HIV Protease; D000069454:Darunavir
Acta Crystallogr D Biol Crystallogr. 1999 Apr;55(Pt 4):938-40
10089341
Eur J Biochem. 1999 Jul;263(1):238-45
10429209
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
10592235
AIDS. 2000 Jan 28;14(2):141-9
10708284
AIDS. 2000 Jun 16;14(9):1203-10
10894285
Proteins. 2001 Jun 1;43(4):455-64
11340661
AIDS. 2001 Jul 27;15(11):1369-77
11504958
Biochemistry. 2002 Apr 9;41(14):4582-94
11926820
J Virol. 2003 Apr;77(8):4836-47
12663790
Eur J Biochem. 2004 Apr;271(8):1516-24
15066177
J Mol Biol. 2004 Apr 23;338(2):341-52
15066436
J Virol Methods. 2004 Aug;119(2):87-93
15158589
Antimicrob Agents Chemother. 2004 Aug;48(8):3122-6
15273130
J Med Chem. 2005 Mar 10;48(5):1297-313
15743172
Minerva Cardioangiol. 2005 Apr;53(2):153-4
15986010
FEBS J. 2005 Oct;272(20):5265-77
16218957
J Med Chem. 2006 Feb 23;49(4):1379-87
16480273
Antimicrob Agents Chemother. 2006 Jun;50(6):2201-6
16723584
ChemMedChem. 2006 Sep;1(9):939-50
16927344
Top HIV Med. 2006 Aug-Sep;14(3):125-30
16946457
J Mol Biol. 2006 Oct 13;363(1):161-73
16962136
Antimicrob Agents Chemother. 2007 Jun;51(6):2143-55
17371811
Methods Enzymol. 1997;277:319-43
18488315
Acta Crystallogr A. 1991 Mar 1;47 ( Pt 2):110-9
2025413
Biochem Biophys Res Commun. 1989 Feb 28;159(1):87-94
2647085
Methods Enzymol. 1997;276:307-26
27754618
Protein Eng. 1994 Mar;7(3):309-17
8177879
Science. 1994 Jan 21;263(5145):380-4
8278812
Annu Rev Biochem. 1993;62:543-85
8352596
J Mol Biol. 1996 Feb 23;256(2):228-34
8594192
J Med Chem. 1996 Aug 30;39(18):3514-25
8784449
Chem Biol. 1996 Apr;3(4):301-14
8807858
Biochemistry. 1996 Oct 1;35(39):12957-62
8841142
N Engl J Med. 1998 Mar 26;338(13):853-60
9516219
Drugs. 1998 Jul;56(1):147-67
9664204